Neoadjuvant hormonal therapy plus surgery for prostate cancer: The MSKCC experience

Surgical Oncology Clinics of North America

Volumn 6, Issue 4, 1997, Pages 831-846

  Fair, W R ^a   Scher, H I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION; HUMAN; METASTASIS; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0030660552     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30306-5     Document Type: Review

References (45)

1. Andros E.A. Danesghari F. Crawford E.D. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate Clin Invest Med 16 6 1993 510 515
2. Aprikian A.G. Fair W.R. Reuter V.E. Experience with neoadjuvant diethyltilboestrol and radical prostatectomy in patients with locally advanced prostate cancer Br J Urol 74 1994 630 636
3. Boxer R.J. Kaufman J.J. Goodwin W.E. Radical prostatectomy for carcinoma of the prostate (1951-1976): A review of 329 cases J urol 117 1977 208 213
4. Bruchovsky N. Rennie P.S. Coldman A.J. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res 50 1990 752 757
5. Colston J.A. Brendler H. Endocrine therapy in carcinoma of the prostate: Preparation of patients for radical perineal prostatectomy J Am Med Asso 134 1947 848 853
6. Eschwege P. Dumas F. Blanchet P. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy Lancet 346 1995 1528 1530
7. Fair W.R. Aprikian A. Sogani P. The role of neoadjuvant hormonal manipulation in localized prostate cancer Cancer 71 1993 1031 1038 suppl
8. Fair W.R. Aprikian A.G. Sogani P. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer Clin Invest Med 16 1993 516 522
9. Gibbons R.P. Correa R.J. Brannen G.E. Total prostatectomy for localized prostatic cancer J Urol 131 1984 73 76
10. Gleave M.E. Goldenberg S.L. Jones E.C. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer J Urol 155 1996 213 219
11. Goldenberg S.L. Klotz L.H. Srigley J. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer J Urol 156 1996 873 877
12. Gomella L.G. Liberman S.N. Mulholland S.G. Induction androgen deprivation plus prostatectomy for stage T3 disease: Failure to achieve prostate-specific antigen-based freedom from disease in a Phase II trial Urology 47 1996 870 876
13. Guttierrez R. New horizons in the surgical management of carcinoma of the prostate Am J Surg 78 1949 147 169
14. Huggins C. Hodges C.V. Studies on prostate cancer: The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
15. Isaacs J.T. Coffey D.S. Adaptation versus selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma Cancer Res 41 1981 5070 5075
16. Israeli R.S. Miller W.H. Jr. Su S.L. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen-based assays Cancer Res 54 1994 6306 6310
17. Kava B.R. Fair W.R. Five-year interim follow-up of forty-seven patients with locally advanced prostate cancer treated with neoadjuvant diethylstilbestrol followed by radical prostatectomy J Urol [AUA Abstract 1298] 1997 in press
18. Kennedy T.J. Sonneland A.M. Marlett M. Lutenizing hormone-releasing hormone downstaging of clinical stage C prostate cancer J Urol 147 1992 891 893
19. Labrie F. Dupont A. Cusan L. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and Lupron: The first controlled and randomized trial Clin Invest Med 16 1993 499 509
20. Labrie F. Endocrine therapy of prostate cancer Endocrinol Metab Clin North Am 20 1991 845 872
21. Lerner S.E. Blute M.L. Zincke H. Extended experience with radical prostatectomy for clinical stage T3-prostate cancer: Outcome and contemporary morbidity J Urol 154 1995 1447 1452
22. Loric S. Dumas F. Eschege P. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen Clin Chem 41 1995 1698 1704
23. MacFarlane M. Abi-Aad A. Stein A. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer J Urol 150 1993 132 134
24. Moreno J.G. Croce C.M. Fischer R. Detection of hematogenous micrometastases in patients with prostate cancer Cancer Res 52 1992 6110 6112
25. Oesterling J.E. Andrews P.E. Suman V.J. Preoperative androgen deprivation therapy: Artificial lowering of serum prostate specific antigen without downstaging the tumor J Urol 149 1993 779 782
26. Parker S.L. Tong T. Bolden S. Cancer statistics, 1996 CA Cancer J Clin 46 1996 5 27
27. Parlow A.L. Scott W.W. Hormone control therapy as a preparation for radical perineal prostatectomy in advanced carcinoma of the prostate NY J Med 49 1949 629 634
28. Parlow A.L. Advanced cancer of the prostate: A consideration of the value of radical prostatecomy in selected cases NY J Med 45 1945 383 387
29. Partin A.W. Kattan M.W. Subong E.N.P. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update J Am Med Asso 277 1997 1445 1451
30. Paulson D.F. Moul J.W. Walther P.J. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: Long-term results J Urol 144 1990 1180 1184
31. Pinault S. Tetu B. Gagnon J. Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with Flutamide Urology 39 1992 254 261
32. Schulman C.C. Sassine A.M. Neoadjuvant hormonal deprivation before radical prostatectomy Clin Invest Med 16 1993 523 531
33. Scott W.W. Boyd H.L. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based on 25 years of experience J Urol 101 1969 86 92
34. Scott W.W. An evaluation of endocrine therapy plus radical prostatectomy in the treatment of advanced carcinoma of the prostate J Urol 1964 97 102
35. Solomon M.H. McHugh T.A. Dorr R.P. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy Clin Invest Med 16 1993 532 538
36. Soloway M.S. Roohollah S. Wajsman Z. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNXM0) prostate cancer J Urol 154 1995 424 428
37. Soloway M.S. Hachiya T. Civantos F. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer Urology 43 [ 1994 52 56 suppl
38. Tetu B. Srigley J.R. Boivin J.C. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: A histopathologic and immunohistochemical study Am J Surg Pathol 15 1991 111 120
39. Tomlinson R.L. Currie D.P. Boyce W.H. Radical prostatectomy: Palliation for stage C carcinoma of the prostate J Urol 117 1977 85 87
40. Vallett B.S. Radical perineal prostatectomy subsequent to bilateral orchiectomy Del Med J 16 1944 19 23
41. van Poppel H. Ridder D.D. Elgamal A.A. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial J Urol 154 1995 429 434
42. van Poppel H. Ameye F. Oyen R. Radical prostatectomy for localized prostate cancer Eur J Surg Oncol 18 1992 456 462
43. Epstein J.I. Can significant prostate cancer be predicted preoperatively in men with Stage T1 disease? Seminars in Urologic Oncology 14 1966 165 173
44. Lerner S.E. Cseay T.M. Blute M.L. Prostate-specific antigen detected prostate cancer (clinical stage T1C): An interim analyses Journal of Urology 155 1966 821 826
45. Cookson M. Results of radical prostectomy in patients with nonpalpable prostate specific antigen (PSA) protected stage (Tlc) prostate cancer Urology 49 1997 887 893